This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TARRYTOWN, N.Y., July 2, 2013 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will make a presentation on Wednesday, July 10
th at 9:00 AM EDT at the JMP Securities Healthcare Conference in New York City. The company overview will be webcast live via a link on the Events page of Progenics' website and archived there for 30 days.
Progenics Pharmaceuticals, Inc. develops innovative medicines for oncology, and has a pipeline that includes product candidates in preclinical through late-stage development. Progenics' first commercial product, Relistor
® (methylnaltrexone bromide) for opioid-induced constipation, is marketed and in further development by Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. is developing the subcutaneous formulation. For additional information, please visit
Additional information concerning Progenics and its business may be available in press releases or other announcements and public filings made after this announcement.
CONTACT: Kathleen Fredriksen